Craig-Hallum initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Approves Amendments at Annual Stockholders Meeting
- Neurogene price target raised to $26 from $22 at BMO Capital
- Neurogene Highlights Gene Therapy Advancements in New Update
- Neurogene Reports Q1 2025 Financial Progress and Updates
- Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue